Table 1 Baseline characteristics of patients by PLR tertiles
Variables | PLR tertiles | P value | ||
|---|---|---|---|---|
T1 (< 112.73) (n = 90) | T2 (112.73–179) (n = 90) | T3 (> 179) (n = 90) | ||
Age (year) | 50.93 ± 10.72 | 49.52 ± 11.65 | 49.52 ± 11.02 | 0.618 |
Sex (male) | 69 (76.67%) | 57 (63.33%) | 63 (70.00%) | 0.149 |
Lymphocyte (109/L) | 1.50 (1.20–2.20) | 1.20 (1.00–1.40) | 0.70 (0.60–1.00) | < 0.001* |
Platelet count (109/L) | 127.50 (95–150.75) | 174 (147.50–215.25) | 181 (148.25–232.75) | < 0.001* |
Hemoglobin (g/L) | 121.70 ± 21.11 | 122.82 ± 19.07 | 121.01 ± 22.10 | 0.840 |
INR | 1.11 (1.04–1.24) | 1.09 (1.01–1.17) | 1.10 (1.04–1.17) | 0.501 |
PT (s) | 14.05 (13.22–15.45) | 13.80 (12.93–14.70) | 14.00 (13.30–14.90) | 0.115 |
APTT (s) | 35.60 (31.85–38.98) | 33.55 (29.65–37.95) | 33.65 (30.70–37.25) | 0.389 |
Smoking | 44 (48.89%) | 36 (40.00%) | 43 (47.78%) | 0.427 |
Alcohol consumption | 31 (34.44%) | 32 (35.56%) | 33 (36.67%) | 0.953 |
Hypertension | 65 (72.22%) | 60 (66.67%) | 62 (68.89%) | 0.719 |
Diabetes mellitus | 3 (3.33%) | 6 (6.67%) | 4 (4.44%) | 0.568 |
Marfan syndrome | 3 (3.33%) | 10 (11.11%) | 4 (4.44%) | 0.067 |
Hemopericardium | 9 (10.00%) | 6 (6.67%) | 10 (11.11%) | 0.564 |
Coronary artery disease | 10 (11.11%) | 7 (7.78%) | 6 (6.67%) | 0.539 |
Cerebrovascular disease | 4 (4.44%) | 4 (4.44%) | 6 (6.67%) | 0.740 |
Chronic renal failure | 5 (5.56%) | 3 (3.33%) | 4 (4.44%) | 0.770 |
Penn class | 0.479 | |||
Class Aa | 55 (61.11%) | 48 (53.33%) | 48 (53.33%) | |
Non class Aa | 35 (38.89%) | 42 (46.67%) | 42 (46.67%) | |
CPB time (min) | 176 (146–207.25) | 174.5 (143.5–202.75) | 176 (144.25–197) | 0.424 |
Ventilator use | 51 (56.67%) | 46 (51.11%) | 51 (56.67%) | 0.688 |
Operative time (hour) | 11 (9–12) | 10 (9–11.75) | 10 (8–12) | 0.344 |
Surgery type | 0.055 | |||
AAR + TAR (TAVR) + FET | 42 (46.67%) | 49 (54.44%) | 42 (46.67%) | |
Bentall + TAR (TAVR) + FET | 27 (30.00%) | 16 (17.78%) | 15 (16.67%) | |
David + TAVR + FET | 1 (1.11%) | 6 (6.67%) | 3 (3.33%) | |
Combine others | 20 (22.22%) | 19 (21.11%) | 30 (33.33%) | |
Autologous blood transfusion (≥ 500 ml) | 20 (22.22%) | 31 (34.44%) | 32 (35.56%) | 0.099 |
Platelet (therapeutic dose) | 0.003* | |||
≤ 1 | 44 (48.89%) | 53 (58.89%) | 66 (73.33%) | |
> 1 | 46 (51.11%) | 37 (41.11%) | 24 (26.67%) | |
Cryoprecipitate (therapeutic dose) | 0.456 | |||
≤ 1 | 53 (58.89%) | 58 (64.44%) | 61 (67.78%) | |
> 1 | 37 (41.11%) | 32 (35.56%) | 29 (32.22%) | |
RBCs (unit) | 0.438 | |||
≤ 10 | 57 (63.33%) | 60 (66.67%) | 65 (72.22%) | |
> 10 | 33 (36.67%) | 30 (33.33%) | 25 (27.78%) | |
Plasma (unit) | 0.099 | |||
≤ 10 | 38 (42.22%) | 52 (57.78%) | 48 (53.33%) | |
> 10 | 52 (57.78%) | 38 (42.22%) | 42 (46.67%) | |
Postoperative in-hospital mortality | 21 (23.33%) | 6 (6.67%) | 9 (10.00%) | 0.002* |